Found: 10
Select item for more details and to access through your institution.
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 176, n. 3, p. 557, doi. 10.1007/s10549-018-05112-9
- By:
- Publication type:
- Article
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 2, p. 351, doi. 10.1007/s10549-018-4767-1
- By:
- Publication type:
- Article
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 158, n. 2, p. 323, doi. 10.1007/s10549-016-3863-3
- By:
- Publication type:
- Article
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 3, p. 543, doi. 10.1007/s10549-015-3634-6
- By:
- Publication type:
- Article
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 275, doi. 10.1007/s10549-015-3612-z
- By:
- Publication type:
- Article
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 151, n. 2, p. 373, doi. 10.1007/s10549-015-3378-3
- By:
- Publication type:
- Article
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
- Published in:
- Breast Cancer Research, 2016, v. 18, p. 1, doi. 10.1186/s13058-016-0771-8
- By:
- Publication type:
- Article
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 6, p. 441, doi. 10.1093/jnci/djs125
- By:
- Publication type:
- Article